F8 and hemophilia: Autologous stem cell transplantation herein for hemophilia associates with ex vivo gene correction using CRISPR/Cas9 editing or AAV and lentivirus (LV) vector -based gene transduction in autologous iPSCs, MSCs, and hemopoietic stem cells (HSCs), and, followed by the transplantation of these corrected cells back into the same individual to enable normal expression of FIX and FVIII.